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ub Choi, MD,Abstract: To reduce hepatitis B virus reinfection after liver trans-
plantation (LT), patients often receive antihepatitis B immunoglobulin
(HBIG) alone or combined with antiviral nucleoside/nucleotide analogs
(NUCs); however, proximal renal tubular dysfunction (RTD) that was
induced by NUCs in liver recipients was rarely reported. Here, we
analyzed RTD and renal impairment (RI) following adefovir (ADV) and
lamivudine (LAM) treatment in liver recipients.
We retrospectively reviewed medical records of patients treated
with HBIG alone (group 1, n¼ 42) or combined with ADV or LAM
(group 2, n¼ 21) after LT. We compared RTD and RI incidence during
the 12 months after LT. An RTD diagnosis required manifestation of at
least 3 of the following features: hypophosphatemia, RI, hypouricemia,
proteinuria, or glucosuria.
No significant differences were observed regarding sex, age, donor
type, model of end-stage liver score, and estimated glomerular filtration
rate at pre-LT between the 2 groups. Hepatitis B virus recurrence within
12 months was 4.8% in both groups (P¼ 1.000); however, the RTD
incidence was 0% in group 1 and 19.0% in group 2 (P¼ 0.010). RI
occurrence did not differ between the groups. The only risk factor for RI
was HBIG administration combined with both LAM and ADV (odds ratio
11.27, 95% confidence interval 1.13–112.07, P¼ 0.039, vs HBIG alone).
RTD occurred more frequently in patients treated with HBIG
combined with LAM or ADV compared with HBIG alone. Thus,
LAM or ADV therapy can induce RTD after LT, and when adminis-
tered, liver recipients should be monitored.
(Medicine 94(38):e1569)
Abbreviations: ADV = adefovir dipivoxil, CNI = calcineurin
inhibitor, eGFR = estimated glomerular filtration rate, ETV =Dong Jin Joo, MD, PhD
nucleotide analogues, RI = renal impairment, RTD = renal tubular
dysfunction, S-Cr = serum creatinine, TAC = tacrolimus.
INTRODUCTION
P revention of hepatitis B virus (HBV) recurrence is importantafter liver transplantation (LT) in patients infected with the
virus. To reduce HBV reinfection following LT, antihepatitis B
immunoglobulin (HBIG) alone or in combination with antiviral
nucleoside/nucleotide analogs (NUCs) is often used as prophy-
laxis1,2; however, NUCs are known to be nephrotoxic.3 In
particular, chronic hepatitis B patients treated with adefovir
dipivoxil (ADV) or lamivudine (LAM) have frequently
reported renal dysfunction and hypophosphatemia.4–6 The
liver recipients are more vulnerable to nephrotoxicity than
other patients due to pretransplant liver cirrhosis, perioperative
bleeding and hypotension, posttransplant calcineurin inhibitor
(CNI) use, and infection.7,8 Renal dysfunction after LT is a very
common adverse effect8 and key prognostic factor of post-LT
survival.9 Although nephrotoxic agents in liver recipients are
used with caution, several studies have reported nephrotoxicity
following LAM and ADV treatment.10–12 The aim of the
current study was to investigate LAM- and ADV-induced
nephrotoxicity in liver recipients through retrospective review
and analysis of incidence, clinical features, risk factors, prog-
nosis of proximal renal tubular dysfunction (RTD), and renal
impairment (RI).
PATIENTS AND METHODS
Patients and Groups
Medical records of liver recipients with HBV who under-
went LT in Yonsei University Severance Hospital between
September 2005 and December 2012 were retrospectively
reviewed. To minimize confounder effects to estimated glo-
merular filtration rate (eGFR), we excluded the following
patients with the following characteristics: <15 years old,
multiorgan transplantation, retransplantation, hepatitis C virus
coinfection, perioperative mortality, cyclosporine treatment
instead of tacrolimus (TAC), and low eGFR (<60mL/min/
1.73 m2). We reviewed 63 liver transplant recipients who had
undergone prophylactic treatment with HBIG, LAM, or ADV
continuously without change for a minimum of 12 months.
Liver recipients were divided into 2 groups according to
whether they were treated with or without ADV and LAM.
Group 1 included recipients who were administered HBIG
alone, whereas Group 2 consisted of patients who received
HBIG combined with ADVor LAM for HBV prophylaxis. Theproved by the independent institutional
i University College of Medicine (IRB
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TABLE 1. Baseline Characteristics of Liver Recipients Who Received Prophylactic Treatment With HBIG Alone (Group 1) or in
Combination With LAM or ADV (Group 2)

Patient Characteristics Group 1 (n¼ 42) Group 2 (n¼ 21) P value
Male recipients, n (%) 36 (85.7%) 16 (76.2%) 0.483
Male donors, n (%) 32 (76.2%) 15(71.4%) 0.762
Age of recipients, y 52.5 6.5 51.1 5.9 0.409
Age of donors, y 34.7 10.5 35.9 13.1 0.703
Living donor, n (%) 35 (83.3%) 16 (76.2%) 0.513
BMI, kg/m3 23.7 2.6 24.1 2.4 0.505
Hypertension, n (%) 8 (19.0%) 5 (23.8%) 0.357
Diabetes, n (%) 8 (19.0%) 6 (28.6%) 0.710
CTP score 8.1 2.2 8.1 2.0 0.866
MELD score 12.3 5.6 11.9 6.6 0.765
HCC pre-LT 22 (52.4%) 9 (42.9%) 0.512
S-Cr, mg/dL 0.84 0.16 0.87 0.16 0.515
eGFR, mL/min/1.73 m2 103.24 024.94 96.32 6.32 4 0.282
Intraoperative transfusion, packs 4.9 5.0 5.7 4.1 0.551
ated
for
s va
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Dysfunction
To evaluate nephrotoxicity due to LAM or ADV treatment,
we compared incidence of RTD and RI for 12 months after LT
between the groups. Although RTD and Fanconi syndrome have
been defined differently in the literature, we used the definition of
RTD suggested byGara et al.4 In particular, RTD is characterized
by hypophosphatemia (ie, serum phosphate <2.5mg/dL and
0.5mg/dL from baseline) with at least 2 other de novo mani-
festations of tubular dysfunction defined as follows4: increase in
serum creatinine (S-Cr)>1.2mg/dL and0.5mg/dL from base-
line; hypouricemia (ie, serumuric acid<3.7mg/dL and0.5mg/
dL from baseline); proteinuria; and glycosuria without diabetes
mellitus.
We defined RI as a sustained increase in S-Cr >1.2mg/dL
and 0.5mg/dL from baseline.4,13
To evaluate renal function, S-Cr and eGFR were compared
between pre-LT and 12 months post-LT in each group and
between groups. eGFR was calculated based upon S-Cr, race,
and age using the updated Modification-of-Diet-in-Renal-Dis-
ease equation.14 CKD stage expressed as base on kidney disease
outcomes quality initiatives (K/DQI) guidelines.15
Antihepatitis B Regimens and
Immunosuppression
We routinely treated HBV-infected LT recipients with
HBIG alone or in combination with NUC as follows. During
the anhepatic phase, 10,000 IU (20,000 IU if HBe Agþ or HBV
DNAþ at pre-LT) of HBIG was infused. During the first week
after LT, 10,000 IU of HBIG was infused daily. For the next
month, 10,000 IU of HBIG was infused once per week. There-
after, 10,000 IU of HBIG was infused once per 4 to 6 weeks to
maintain a trough serum level >500 IU/L. LAM (100mg) and
ADV (10mg) were administrated orally in patients with normal
renal function. These doses were reduced in patients with
creatinine clearance was <50mL/min.
ADV¼ adefovir dipivoxil, BMI¼ body mass index, eGFR¼ estim
HCC¼ hepatocellular carcinoma, LAM¼ lamivudine, MELD¼Model
Data are expressed as the mean standard deviation for continuouThe standard protocol for maintaining immunosuppression
consisted of TAC, steroids, and mycophenolate mofetil in our
institution. Double regimens (eg, TAC and steroid) were
2 | www.md-journal.comconsidered for patients with gastrointestinal conditions, leuko-
penia, cytomegalovirus infection, and for women in their child-
bearing years. The trough level of TAC in triple regimens was
6 to 12 ng/mL for the first month and 5 to 8 ng/mL thereafter.
In double regimens, the trough level of TAC was 8 to 15 ng/mL
for the first month and 6 to 10 ng/mL thereafter.
Serum and Urine Monitoring in Outpatients
after LT
All HBV-infected patients were examined for complete
blood count and routine chemistries, including serum aspartate
aminotransferase, alanine aminotransferase, alkaline phospha-
tase, direct and total bilirubin, creatinine, blood urea nitrogen,
phosphate, calcium, uric acid, albumin, total protein, and
phosphate every 4 to 6 weeks. The serum level of hepatitis
surface antibody (Hbs Ab) was also assessed every 4 to 6 weeks.
Another HBV serologic panel [hepatitis surface antigen
(HBs Ag), hepatitis envelope antigen (HBe Ag), and hepatitis
enevelope antibody (HBe Ab)] and HBV DNA were tested at
least once per year. Alpha-fetoprotein and protein induced by
vitamin K antagonist-II (PIVKA-II) was measured every 2 or
3 months in recipients with hepatocellular carcinoma (HCC).
Urinalysis was also checked every 2 or 3 months.
Statistical Analysis
Data are expressed as the mean ( standard deviation) for
continuous variables and number (proportion) for categorical
variables. Statistical analysis was performed using the SPSS
20 (SPSS Inc., Chicago, IL). Categorical variables were tested
using Fisher exact test or chi-square test between groups. Con-
tinuous variables were tested using independent Student t tests.
Differences in eGFR and S-Cr between pre-LT and 12 months
post-LT in each group were compared using the paired Student t
test. Changes in distribution of CKD stages in each group were
evaluated by the Wilcoxon signed-rank test. Survival rates were
calculatedusingKaplan–Meier analysis and the log-rank testwas
glomerular filtration rate, HBIG¼ antihepatitis B immunoglobulin,
End-stage Liver Disease, S-Cr¼ serum creatinine.
riables and number (proportion) for categorical variables.used to compare the probabilities in subgroups. The risk factor of
RI was calculated by logistic regression. A P value<0.05 was
considered statistically significant.
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considered because liver recipients are vulnerable to kidney
injuries.7 Nephrotoxicity following CNI treatment has been well
established in liver recipients16; however, nephrotoxicity due to
TABLE 2. Changes in Renal Function between Pre-LT and 12 Months Post-LT Based on HBV Prophylaxis Regimens

Renal Function
Group 1 Group 2
P Value
(Group 1 vs 2)aPre-LT
1-Year
Post-LT P Value Pre-LT
1-Year
Post-LT P Value
S-Cr, mg/dL 0.84 0.16 1.23 0.28 <0.001 0.87 0.16 1.23 0.31 <0.001 0.736
eGFR, mL/min/1.73 m2 103.24 25.34 66.19 25.33 <0.001 96.32 21.31 66.18 18.60 <0.001 0.295
eGFR¼ estimated glomerular filtration rate, LT¼ liver transplantation, S-Cr¼ serum creatinine.
Data represent the mean standard deviation.
s (c
FIGURE 1. Distribution according to stages of CKD based on
kidney disease outcomes quality initiatives guidelines15 at pre-
LT and 12 months post-LT. In both groups, the proportion of CKD
stage 1 was significantly decreased and that of CKD stage 3 was
remarkably increased at 12 months after liver transplantation;
however, no significant differences in changes of CKD stages,
from baseline to 12 month after LT, were observed between
Medicine  Volume 94, Number 38, September 2015 Renal Tubular Dysfunction in Liver RecipientsRESULTS
The number of LT recipients who had undergone prophy-
lactic treatment with HBIG alone or in combination with LAM
or ADV totaled 63, of which 52 were male and 51 received an
organ from a living donor. The mean age was 52.0 6.3 years,
with 42 and 21 recipients assigned into groups 1 and 2,
respectively. No significant differences were observed between
the groups regarding sex, age, body mass index, hypertension,
diabetes mellitus, Child–Turcotte–Pugh score, the Model for
End-stage Liver disease score, S-Cr and eGFR pre-LT, and
intraoperative transfusion. The demographic characteristics of
the liver recipients are summarized in Table 1.
We began our retrospective study by examining the recur-
rence of HBV and HCC. Our analysis revealed that the rate of
HBV recurrence within 12 months was 4.8% in both groups
(P¼ 1.000). The rate of hepatocellular carcinoma (HCC) recur-
rence during this time period was similar to HBV recurrence,
with 7.1% and 4.8% of patients in groups 1 and 2, respectively
(P¼ 1.000), re-experiencing HCC. The level of HBV DNA in
patients who had developed HBV recurrence was higher than
104 and 2 patients were positive for HBe Ag before transplan-
tation. All 3 patients were switched to treatment with HBIG plus
entecavir (ETV) from HBIG alone or in combination with
LAM. Two patients died due to HCC recurrence but 1 patient
survived with normal liver function. Patients who experienced
HBV recurrence exhibited a mean survival rate of 39 months
(ranging from 27 to 75 months).
Next, we assessed the effect of LT on eGFR. The mean
eGFR at 12 months after transplantation was significantly
reduced compared with before transplantation in each group
(P< 0.001). The changes of eGFR and S-Cr observed were not
significantly different between the groups. The details of renal
function are shown in Table 2. The distribution according to
CKD stages changed over time in each group. The proportion of
CKD stage 1 was significantly decreased in both groups after
12 months, whereas the proportion of CKD stage 3 increased
(P< 0.001, Figure 1.)
Examination of RTD revealed that 4 patients were diag-
nosed with this condition after LT. Only group 2 consisted of
RTD patients (0.0% vs 19.0%, P¼ 0.010). All patients diag-
nosed with RTD exhibited symptoms of hypophosphatemia and
hypouricemia. Among them, 1 patient with HCC recurrence
died at 60 months after LT. The clinical manifestations of all
RTD recipients are shown in Table 3.
The percentage of RI that occurred within 12 months was
aP values were calculated to compare renal function between group26.2% and 28.6% in groups 1 and group 2, respectively
(P¼ 1.000). The only risk factor for RI was administration
of HBIG combined with both LAM and ADF (OR 11.27, 95%
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.CI 1.13–112.07, P¼ 0.039, compared with HBIG alone) by
logistic regression analysis. The ages of the donors and reci-
pients, sex, donor type, intraoperative transfusion, theModel for
End-stage Liver disease score, Child–Turcotte–Pugh score,
hypertension, diabetes mellitus, and pre-LT eGFR did not
exhibit statistically significant differences.
Finally, no significant differences were found in survival
rate between groups 1 and 2 (87.1% vs 85.7% at 3 years, 87.1%
vs 75.9% at 5 years, P¼ 0.395). This rate was not affected by
RTD (66.7% and 81.2% at 5 years, P¼ 0.831) or RI (86.7% and
86.4% at 3 years, 86.7% and 80.8% at 5 years, P¼ 0.831).
DISCUSSION
Renal dysfunction is a common complication after LT,7 and
the decrease in post-LT eGFR over time is associated with post-
LT survival.9 Careful use of nephrotoxic drugs after LT should be
hange from baseline).the groups. CKD¼ chronic kidney disease, LT¼ liver transplan-
tation.

P value calculated by Wilcoxon signed-rank test in each
group. yP value calculated by comparing changes from baseline
using Fisher exact test.
www.md-journal.com | 3
TABLE 3. Clinical Features of 4 Liver Recipients Who Developed RTD

No Age Sex
Phos
(mg/dL)
Cr
(mg/dL)
Uric Acid
(mg/dL)
Urine
Protein
Urine
glucose NUC Status
Follow-Up
(Months)
1 47 M 3.9/1.1 1.10/1.20 4.6/1.5 / /4þ LAM!ETV Alive 92
2 43 M 3.0/1.7 0.90/0.90 4.1/2.3 / /þ LAM!ETV Alive 74
3 48 M 3.7/2.2 1.00/2.04 4.1/2.2 /2þ 2þ/3þ LAMþADF!ETV Alive 39
4 47 F 3.0/2.5 0.70/0.74 3.7/3.3 / /1þ LAM Dead 60
ADF¼ adefovir dipivoxil, Cr¼Creatinine, ETV¼ entecavir, LAM¼ lamivudine, NUC¼ nucleoside/nucleotide, Phos¼ phosphate, RTD¼ renal
TD
Lee et al Medicine  Volume 94, Number 38, September 2015NUC treatment is less understood. Small number of case studies
regarding RTD of NUC was reported in liver recipients.11,12
ADV is nucleotide analog of adenosine monophosphate
that is highly effective in viral suppression in both treatment-
naive and LAM-resistant chronic hepatitis B (CHB) patient.17
Although ADV nephrotoxicity was dose-dependent, adminis-
tration of 10mg was also reported as an independent predictor
for significant renal dysfunction (defined as eGFR 50mL/
min/1.73 m2).6 LAM is a nucleoside analog that targets the
reverse transcriptase of HBV and probably remains the most
widely used NUC due to its low cost18; however, long-term
lamivudine therapy results in viral resistance due to YMDD
mutations.19 Therefore, combination treatment of ADV with
LAM has been recommended for treating LAM-resistant HBV.
Renal function declines over time with LAM treatment20 and
RTD is common, especially in patients treated with LAM and
ADV.5
In contrast to CNI toxicity, which is a major factor of
chronic kidney disease after LT that affects vasoconstric-
tion,16,21 the nephrotoxicity of NUC influences the renal prox-
imal tubule.3 The characteristics of CNI-induced tubular
damage include renal tubular functional alternation and meta-
bolic disturbance like hyperkalemia, hypomagnesemia, distal
renal tubular acidosis, and hyperuricemia.21 On the contrary,
the clinical features of RTD due to NUC treatment are hypo-
phosphatemia, hypouricemia, increased S-Cr, glucosuria, and
proteinuria.3–5
In our study, 4 recipients from group 2 were diagnosed
with RTD within 12 months after transplantation. The cumu-
lative incidence of RTD after 1 year was 19.0%, which was
higher than the 15% after 10 years reported by Gara et al4 and
the 6.8% after 1 year published by Tanaka et al5; however, these
studies evaluated nontransplant patients, whereas our study
investigated the effects of these NUCs on liver transplant
recipients. We propose several possibilities to explain why
RTD incidence was found to be higher in our study. First, liver
recipients are more susceptible to kidney injury than nontrans-
plant patients with CHB due to a combination of hemodynamic
instability, CNI toxicity, nephrotoxic drug, and acute tubular
necrosis.7 The mean eGFR at 12 months post-LT in recipients
administered HBV prophylaxis was decreased from baseline in
our study (Table 2 and Figure 1). Sharma et al9 also reported that
eGFR of liver recipients decreased over time after LT.
Second, a synergistic effect due to interaction between
immunosuppressants, NUCs, and other nephrotoxic drugs can
cause more severe nephrotoxicity. Due to the small number of
tubular dysfunction.
Data are expressed as the value at baseline/value at diagnosis of RRTD patients included in our study, we could not find any other
significant risk factors of RTD except HBV prophylaxis with
ADV or LAM; however, all RTD patients were administered
4 | www.md-journal.comimmunosuppressants with dual regimens including TAC and a
steroid. The level and dosage of CNI is generally higher than
that of triple regimens including TAC, steroids, and
mycophenolate mofetil. The synergic effect between a NUC
and CNI is not well understood; however, development of renal
Fanconi syndrome due to TAC and LAM treatment has been
reported.11 We hypothesize that a synergic effect can occur
between CNI and NUC that causes nephrotoxicity.
Third, RTD incidence may also be high due to improper
dosing of NUC. Because NUC nephrotoxicity is well estab-
lished, the European Association for the Study of the Liver
recommended that dosage should be adjusted in all patients with
impaired renal function (defined as creatinine clearance
50mL/min)22; however, improper dosing is not the main
cause of RTD because we excluded a patient with a pre-LT
eGFR <60mL/min/1.73 m2. We confirmed the dosage taken
by the patient who developed RTD according to creatinine
clearance.
A treatment regimen of HBIG combined with NUCs is
commonly prescribed; however, the most effective prophylactic
option following LT remains controversial.1,2 The recurrence
rate of HBV was reported in 0% to 32% patients in HBIG
monotherapy.1 In our study, no significant differences in HBV
recurrence rate were observed between patients treated with
HBIG alone and in combination with LAM or ADV. The
cumulative incidences of HBV recurrence were 4.8% in both
groups 1 and 2 during the initial 12 months after LT. There were
limitations to control variables that could affect HBV recur-
rence, such as HBe Ag and the level of HBV DNA at pre-LT
because we focused primarily on nephrotoxicity due to LAM
and ADV; however, we suggest that HBIG monotherapy can be
considered for patients diagnosed with RTD after LT because
this condition can be induced by NUCs.
HBV prophylaxis regimens, RI, and RTD did not affect
survival rate in our study. Sharma et al9 reported that a decrease
in post-LT eGFR over time was the only independent predictor
of survival as patients were divided into 3 groups according to
pre-LT eGFR (60mL/min/1.73 m2, 30–59mL/min/1.73 m2
and <30mL/min/1.73 m2). In contrast, we excluded a patient
with eGFR <60mL/min/1.73 m2 before transplantation to
evaluate NUC nephrotoxicity in liver recipients with normal
renal function. Furthermore, we selected patients who did not
change their HBV prophylaxis regimen for a minimum of
12 months to determine the difference in nephrotoxicity
between HBIG alone and in combination with LAM or
ADV. This can be 1 reason why the current study does not
.demonstrate a negative effect of RI and RTD to graft survival.
Also, RTD did not affect survival because this condition can be
reversed with cessation of nephrotoxic drugs; GFR was also
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
preserved unlike glomerulonephropathy.23,24 In our study, none
of the RTD patients progressed to symptomatic hypophosphate-
mia such as osteomalacia. Three RTD patients showed improve-
ments in serum phosphate, creatinine, uric acid, and glucosuria
after switching to ETV. These results are consistent with Gara
et al, who also reported that 6 RTD patients exhibited improve-
ment after switching fromADV or tenofovir to ETV.4 Therefore,
changing antiviral agents is a good option when liver recipients
develop RTD.
CONCLUSIONS
It has been convinced that the regimens of HBIG combined
with LAM or ADV had nephrotoxicity in LT recipients. Our
study revealed that HBV prophylaxis regimen including HBIG
combined with ADV or LAM could be associated RTD and
characterized by hypophosphatemia, hypouricemia, RI, gluco-
suria, and proteinuria in liver transplant recipients. A regimen of
HBIG combined with both ADV and LAM could be a risk factor
for RI, which is characterized clinically by elevated S-Cr. RTD
and RI arising from LAM or ADV use should be considered and
monitored in patients who received HBV prophylaxis after LT.
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